N/A N=32 Evaluating the Impact of Synthetic Cooling Agents in Combustible Cigarettes on Smoking Perceptions and Use
Cigarette Smoking-Related Carcinoma
Primary: Cigarette Chemical Contents — 22.86; 22.30; 21.42; 1.64 mg/g of tobacco rod
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=86 Nonopioid Pain Control Regimen After Arthroscopic Hip Procedures
Hip Arthroscopy
Primary: Change in Pain Score — 4.3; 4.4; 1.8; 1.7 score on a scale
Early Phase 1 N=34 PRevention Of Methamphetamine Use Among Postpartum Women Trial (PROMPT)
Methamphetamine-dependence · Postpartum Abstinence
Primary: Successful Recruitment and Randomization of 40 Postpartum Women Into the PROMPT Study — 16; 14; 2; 2 Participants
Phase 3 N=148 A Research Study to See How a New Weekly Insulin, Insulin Icodec When Given Along With Semaglutide Helps in Reducing the Blood Sugar Level in Patients With Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Change in Glycated Haemoglobin (HbA1c) — -1.23 Percentage (%) of HbA1c — p=<0.0001
N/A N=30 Pharmacopuncture Therapy for Chronic Knee Pain
Chronic Knee Pain
Primary: Knee Pain Numeric Rating Scale, NRS — 3.15; 5.20 scores on a scale
Phase 2 N=27 A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS).
Progressive Familial Intrahepatic Cholestasis · Alagille Syndrome · Cholestatic Liver Disease
Primary: Frequency of Treatment-emergent Adverse Events [TEAEs] — 16; 10; 4; 3 Participants
N/A N=77 The Impact of a Resistance Training Intervention on Blood Pressure Control in Older Adults With Sarcopenia
Sarcopenia · High Blood Pressure · Hypertension
Primary: Change in Blood Pressure — 125.5; 131.4; 125.0; 127.5 mmHg
N/A N=40 Ultrafiltration in Pediatric Cardiac Surgery: An Observational Cohort Study
Congenital Heart Disease · Inflammation
Primary: Inflammatory Mediator C3a — 30 pg/ml
Phase 3 N=711 Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
Locally Advanced or Metastatic Unresectable Urothelial Cancer
Primary: Overall Survival (OS) — 10.3; 9.0 months — p=0.0870
N/A N=20 Effects of Administration of SCFA in Rheumatoid Arthritis Inadequate Responders
Rheumatoid Arthritis
Primary: Change From Baseline in Microbiome Alpha Diversity — 0.19 index
Phase 4 N=61 Optimal Blood Pressure Treatment Thresholds Postpartum
Hypertensive Disorder of Pregnancy · Pre-Eclampsia · Hypertension
Primary: Percent of Participants Eligible, Enrolled and Retained (Feasibility) — 61 Participants
Phase 2 N=158 A Study of TAK-341 in Treatment of Multiple System Atrophy
Multiple System Atrophy
Primary: Change From Baseline in Modified Unified Multiple System Atrophy Rating Scale (UMSARS) Part I Total Score at Week 52 — 5.58; 5.54 score on a scale — p==0.961
Phase 1 N=6 A Gene Therapy Study in Patients With Gaucher Disease Type 1
Gaucher Disease, Type 1
Primary: Number of Participants With Treatment-emergent Adverse Events Over Time — 6; 6; 6; 2 Participants
N/A N=40 Personalized Nutrition Delivery to Improve Resilience in Older Adult Trauma Patients
Trauma · Critical Illness
Primary: Number of Patients Recruited — 28; 12 Participants
N/A N=121 Pivotal Study of the NanoKnife System for the Ablation of Prostate Tissue
Prostate Cancer
Primary: Number of Participants With a Negative In-field Biopsy at 12 Months — 86; 35 Participants